Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2013
03/26/2013US8404662 Cyclodextrin-based polymers for therapeutics delivery
03/26/2013US8404250 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
03/26/2013US8403910 Drug releasing coatings for medical devices
03/26/2013CA2531485C Malonamide derivatives
03/26/2013CA2457925C Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
03/26/2013CA2312000C Mammalian cytokine-like polypeptide-10
03/21/2013WO2013040556A1 Compositions of jasmonate compounds and methods of use
03/21/2013WO2013040504A2 Srpx for treatment of cancer
03/21/2013WO2013040439A2 CBP and p300-MEDIATED TRANSCRIPTION MODULATORS AND RELATED METHODS
03/21/2013WO2013040436A2 Esx-mediated transcription modulators and related methods
03/21/2013WO2013040337A1 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
03/21/2013WO2013040286A2 Pharmaceutical compositions
03/21/2013WO2013040233A1 Controlling regulatory t cell function
03/21/2013WO2013040044A1 Aminopyrimidine derivatives for use as modulators of kinase activity
03/21/2013WO2013040027A1 Reprogramming immune environment in breast cancer via dendritic cells
03/21/2013WO2013039916A1 Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
03/21/2013WO2013039880A1 Biomarkers and therapeutic targets of hepatocellular cancer
03/21/2013WO2013039859A1 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
03/21/2013WO2013039851A1 Optical agents for imaging and visualization of matrix metalloproteinase enzymes
03/21/2013WO2013039764A1 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
03/21/2013WO2013039488A1 Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
03/21/2013WO2013039197A1 IκB KINASE α ACTIVATION INHIBITOR
03/21/2013WO2013039111A1 Nano-particles for internal radiation therapy of involved area, and therapy system
03/21/2013WO2013038997A1 Pharmaceutical composition and manufacturing method therefor
03/21/2013WO2013038907A1 Method for inhibiting cell growth, nucleic acid molecule having rna interference effect on nek10 variant gene, and anticancer agent
03/21/2013WO2013038395A1 Transition metal complexes for pharmaceutical applications
03/21/2013WO2013038392A1 Peptides useful for binding to b-cell leukemic cells, conjugates, and compositions comprising same and uses thereof
03/21/2013WO2013038362A1 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
03/21/2013WO2013038195A2 Pharmaceutical nanoparticle compositions
03/21/2013WO2013038189A1 New enzyme inhibitor compounds
03/21/2013WO2013038157A1 Phytocannabinoids for use in the treatment of cancer
03/21/2013WO2013038134A1 Synthesis and anticancer activity of ruthenium (11) cis-cis-1,3,5- triaminocyclohexane complexes
03/21/2013WO2013037964A1 Anticancer active ingredient derived from guiera senegalensis
03/21/2013WO2013037943A1 Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
03/21/2013WO2013037896A1 Disubstituted 5-fluoro-pyrimidines
03/21/2013WO2013037894A1 Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
03/21/2013WO2013037800A1 Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
03/21/2013WO2013037487A1 A particulate system for use in diminishing cell growth/inducing cell killing
03/21/2013WO2013037482A1 Farnesoid x receptor agonists for cancer treatment and prevention
03/21/2013WO2013037390A1 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
03/21/2013WO2013037333A1 6, 8- disubstituted purine compositions and their pharmaceutical and cosmetic use
03/21/2013WO2013037293A1 N-indol-1-amide compounds and application as anticancer medicament
03/21/2013WO2013037292A1 Substituted aromatic urea compound and use thereof as anti-cancer drug
03/21/2013WO2013037129A1 Antitumour pharmaceutical composition with two active components and use thereof
03/21/2013WO2013037127A1 Antitumour pharmaceutical composition and use thereof
03/21/2013WO2013037090A1 Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof
03/21/2013WO2013037043A1 Combination therapy using ribavirin as eif4e inhibitor
03/21/2013WO2013009701A3 Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
03/21/2013WO2012168885A9 Bisacodyl and its analogues as drugs for use in the treatment of cancer
03/21/2013WO2012162257A3 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
03/21/2013WO2012161545A3 Composition for promoting apoptosis or inhibiting cell growth, comprising epstein-barr virus microrna
03/21/2013WO2012158989A9 Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
03/21/2013WO2012154975A3 Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
03/21/2013WO2012145535A3 Animal model of human cancer and methods of use
03/21/2013WO2012143497A3 Novel binder-drug conjugates (adcs) and their use
03/21/2013WO2012143496A3 Novel binder-drug conjugates (adcs) and their use
03/21/2013WO2012135592A3 Theranostic imaging agents and methods of use
03/21/2013US20130074218 Method for optimising gene expression using synonymous codon optimisation
03/21/2013US20130074201 Cancer-specific genetic rearrangements
03/21/2013US20130072667 Use of rgm and its modulators
03/21/2013US20130072564 Peptide and small molecule agonists of epha and their uses
03/21/2013US20130072550 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
03/21/2013US20130072539 Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand
03/21/2013US20130072522 Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
03/21/2013US20130072511 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
03/21/2013US20130072507 Combination
03/21/2013US20130072495 Fused bicyclic kinase inhibitors
03/21/2013US20130072493 N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
03/21/2013US20130072481 mTOR SELECTIVE KINASE INHIBITORS
03/21/2013US20130072480 Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators
03/21/2013US20130072468 Substituted piperazines as cb1 antagonists
03/21/2013US20130072457 Pyrazolyl quinazoline kinase inhibitors
03/21/2013US20130072425 Saposin-a derived peptides and uses thereof
03/21/2013US20130072421 Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
03/21/2013US20130071482 Block copolymer cross-linked nanoassemblies as modular delivery vehicles
03/21/2013US20130071466 Methods and compositions for treating gastric disorders
03/21/2013US20130071432 Combination virotherapy for cancer
03/21/2013US20130071411 Iap bir domain binding compounds
03/21/2013US20130071407 Methods for modulating hematopoiesis and vascular growth
03/21/2013US20130071403 Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
03/21/2013US20130071382 Egfr mutations
03/21/2013US20130071351 Combination therapy
03/21/2013US20130071350 Method and compositions for treatment of cancers
03/21/2013US20130071326 Universal cell-directed theranostics
03/21/2013US20130071323 Therapies for hematologic malignancies
03/21/2013US20130071320 Immunotherapy of autoimmune disorders using antibodies which target b-cells
03/21/2013CA2848809A1 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
03/21/2013CA2848724A1 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
03/21/2013CA2848616A1 Disubstituted 5-fluoro-pyrimidines
03/21/2013CA2848615A1 Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
03/21/2013CA2848540A1 Therapeutic compounds
03/21/2013CA2848506A1 Certain chemical entities, compositions, and methods
03/21/2013CA2848453A1 Combination therapy using ribavirin as eif4e inhibitor
03/21/2013CA2848410A1 Rna engineered t cells for the treatment of cancer
03/21/2013CA2848311A1 Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
03/21/2013CA2848219A1 Compositions of jasmonate compounds and methods of use
03/21/2013CA2848210A1 Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
03/21/2013CA2848017A1 Use of 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methylpropyl]amino-3,4-dihydro- 2h-1,5-benzoxathiepine for treating cancer and in particular for preventing and/or treating cancer metastases
03/21/2013CA2847842A1 Pharmaceutical compositions
03/21/2013CA2847266A1 New enzyme inhibitor compounds
1 ... 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 ... 2211